Login
Home / ATRA : NASDAQ
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Atara Biotherapeutics, Inc.

$9.25 -$8.52 (-47.95%)
NASDAQ · 14 Sep 2026 20:00 UTC
Previous Close
$9.38
Day Range
$9.09$9.66
Year Range
$3.92$19.14
Market Cap
83.34M
AVG Volume
1.43M
Trailing/Forward PE
-7.84/9.83
PEG ratio
0.03
Dividend Yield
-
Next Earnings Date
2026-11-11
Primary Exchange
NASDAQUS
Revenue (USD)
025M50M75M100M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Net Income (USD)
-40M-20M020M40M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Operating Income (USD)
-40M-20M020M40M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EBITDA (USD)
-40M-20M020M40M60M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash Flows (USD)
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EPS (USD)
-7.5-5-2.502.5524 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Expenses (USD)
-20M020M40M60MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash & Debt (USD)
020M40M60M80MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Debt ratios
-6-4-20224 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Margins
0%25%50%75%100%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Return on Capital
-100%-50%0%50%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Shares Outstanding
05M10M15M20M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Book Value Per Share (USD)
-20-15-10-5024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Total Assets (USD)
050M100M150M200M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Employee Count
02004006002016201720182019202020212022202320242025
PE Ratio
010203040med 7.98Aug 25Oct 25Nov 25Jan 26Feb 26Mar 26May 26
Free Cash Flow Yield
-300%-200%-100%0%med -75.47%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Sales
0102030med 0.78Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
EV/EBITDA
2.557.51012.5med 7.59Aug 25Oct 25Nov 25Jan 26Feb 26Mar 26May 26
Price to Book
0102030med 2.83Feb 22May 22Sep 22Dec 22Mar 23Jul 23Oct 23
Atara Biotherapeutics, Inc.
ATRA
Stockpicker

Video analysis: ATRA

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ATRA

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

businesswire.com · 12 Aug 2026

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026 and business updates. “This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with the.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.